# A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

> **NCT05533775** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 65 (estimated)

## Conditions studied

- Mature B-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Glofitamab
- **DRUG:** Rituximab
- **DRUG:** Ifosfamide
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05533775
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-16
- **Primary completion:** 2029-11-30
- **Final completion:** 2032-11-30
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05533775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05533775, "A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05533775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*